CD62E抗体;CD62E Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using CD62E mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Jurkat cells using CD62E mouse mAb (green) and negative control (red).    

  
  

CD62E, also known as E-selectin or endothelial-leukocyte adhesion molecule-1 (ELAM-1), is a cell surface glycoprotein belonging to the selectin family. It is primarily expressed by activated endothelial cells in response to inflammatory cytokines like TNF-α or IL-1β. CD62E mediates the initial tethering and rolling of leukocytes on vascular endothelium during inflammation, facilitating their extravasation into tissues. This adhesion molecule recognizes sialylated carbohydrate ligands, such as sialyl Lewis X (sLeX), on circulating immune cells.

CD62E antibodies are tools developed to target and study the function of this protein. They play a critical role in research exploring leukocyte-endothelial interactions, inflammatory diseases (e.g., atherosclerosis, sepsis), and cancer metastasis. In therapeutic contexts, anti-CD62E antibodies have been investigated for blocking pathological leukocyte recruitment in autoimmune disorders or ischemia-reperfusion injury. Commercially available CD62E antibodies are widely used in techniques like flow cytometry, immunohistochemistry, and functional inhibition assays. Their specificity enables the identification of activated endothelial cells in tissues and the evaluation of E-selectin expression dynamics under various stimuli. Despite promising preclinical results, clinical translation remains limited, partly due to redundancy in leukocyte adhesion pathways. Ongoing studies continue to explore CD62E's role as a biomarker and therapeutic target in vascular inflammation-related pathologies.